Brokerage Firm Rating on Merck & Company (MRK)

Merck & Company (MRK) : Zacks Investment Research ranks Merck & Company (MRK) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 2.17, which indicates as a Buy.

Merck & Company (MRK) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $57. The average forecast of all the analysts is $64.5 and the expected standard deviation is $7.42.


Merck & Company (NYSE:MRK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $62.61 and $62.48 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $63.73. The buying momentum continued till the end and the stock did not give up its gains. It closed at $63.63, notching a gain of 1.58% for the day. The total traded volume was 10,365,025 . The stock had closed at $62.64 on the previous day.

In a related news, The Securities and Exchange Commission has divulged that Frazier Kenneth C, director officer (Chairman, President & CEO) of Merck & Co., Inc., had unloaded 392,000 shares at an average price of $61.95 in a transaction dated on August 5, 2016. The total value of the transaction was worth $24,284,400.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.